Covered recipient · General Payments record
OMID HAMID
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$151,012.98
90 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $106,925.00 | 33 |
| Consulting Fee | $32,169.03 | 19 |
| Travel and Lodging | $10,524.00 | 22 |
| Food and Beverage | $1,312.96 | 15 |
| Education | $81.99 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $90,940.89 | 54 |
| ARRAY BIOPHARMA INC | $12,143.73 | 6 |
| PFIZER INC. | $7,300.00 | 2 |
| GENZYME CORPORATION | $7,026.17 | 4 |
| Janssen Global Services, LLC | $6,500.00 | 1 |
| Merck Sharp & Dohme LLC | $6,387.50 | 3 |
| Immunocore Limited | $5,463.49 | 6 |
| Novartis Pharmaceuticals Corporation | $4,625.45 | 3 |
| Regeneron Pharmaceuticals, Inc. | $3,815.66 | 3 |
| Regeneron Healthcare Solutions, Inc. | $3,281.00 | 1 |
| EISAI INC. | $1,360.00 | 1 |
| Alkermes, Inc. | $987.10 | 3 |
| Hexal AG | $600.00 | 1 |
| Grifols, S.A. | $500.00 | 1 |
| AVEO Pharmaceuticals, Inc. | $81.99 | 1 |
Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
OMID HAMID
NPI 1215966775 · CMS profile ID 55583
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
SANTA MONICA, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1215966775?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- OMID HAMID, NPI 1215966775, CMS profile ID 55583. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215966775?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). OMID HAMID, NPI 1215966775, CMS profile ID 55583. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215966775?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- OMID HAMID, NPI 1215966775, CMS profile ID 55583, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1215966775?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
90 matching records · $151,012.98 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–90 of 90.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $643.96 | 05/11/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788499 | CMS |
| E.R. Squibb & Sons, L.L.C. | $5,625.00 | 05/10/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788309 | CMS |
| E.R. Squibb & Sons, L.L.C. | $5,625.00 | 05/10/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788311 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,650.00 | 05/10/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788345 | CMS |
| E.R. Squibb & Sons, L.L.C. | $795.67 | 05/06/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788291 | CMS |
| E.R. Squibb & Sons, L.L.C. | $28.50 | 05/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788295 | CMS |
| Merck Sharp & Dohme LLC | $1,907.50 | 05/06/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944618241 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.82 | 05/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788329 | CMS |
| E.R. Squibb & Sons, L.L.C. | $604.05 | 05/05/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788467 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,543.00 | 05/05/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788471 | CMS |
| E.R. Squibb & Sons, L.L.C. | $115.21 | 05/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788473 | CMS |
| E.R. Squibb & Sons, L.L.C. | $27.31 | 05/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788485 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,650.00 | 05/03/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788369 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4,310.00 | 05/03/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788459 | CMS |
| E.R. Squibb & Sons, L.L.C. | $170.00 | 05/03/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788461 | CMS |
| E.R. Squibb & Sons, L.L.C. | $701.54 | 04/28/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788305 | CMS |
| E.R. Squibb & Sons, L.L.C. | $124.25 | 04/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788307 | CMS |
| AVEO Pharmaceuticals, Inc. | $81.99 | 04/27/2022 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950106107 | CMS |
| E.R. Squibb & Sons, L.L.C. | $300.00 | 04/27/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788495 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,650.00 | 04/26/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788287 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,162.16 | 04/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788317 | CMS |
| E.R. Squibb & Sons, L.L.C. | $98.67 | 04/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788319 | CMS |
| Pfizer Inc. | $3,650.00 | 04/26/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048250571 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4,310.00 | 04/19/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788263 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4,310.00 | 04/12/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788341 | CMS |
| Alkermes, Inc. | $650.00 | 04/11/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 925860587 | CMS |
| E.R. Squibb & Sons, L.L.C. | $422.78 | 04/01/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788457 | CMS |
| E.R. Squibb & Sons, L.L.C. | $121.89 | 03/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788261 | CMS |
| E.R. Squibb & Sons, L.L.C. | $477.01 | 03/31/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788271 | CMS |
| E.R. Squibb & Sons, L.L.C. | $244.34 | 03/31/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788273 | CMS |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 03/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788339 | CMS |
| E.R. Squibb & Sons, L.L.C. | $335.10 | 03/30/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788343 | CMS |
| ARRAY BIOPHARMA INC | $3,900.00 | 03/29/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949654341 | CMS |
| GENZYME CORPORATION | $2,552.00 | 03/17/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938902269 | CMS |
| EISAI INC. | $1,360.00 | 03/04/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908072367 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,635.00 | 02/22/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788247 | CMS |
| PFIZER INC. | $3,650.00 | 02/22/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949074907 | CMS |
| Regeneron Healthcare Solutions, Inc. | $3,281.00 | 02/15/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927192603 | CMS |
| Janssen Global Services, LLC | $6,500.00 | 02/12/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887126735 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,650.00 | 01/25/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932788245 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $3,552.78 | 10 |
| PY2025 | Principal investigator | $2,050,900.19 | 353 |
| PY2024 | Recipient | $3,313.87 | 12 |
| PY2024 | Principal investigator | $1,029,726.05 | 139 |
| PY2023 | Recipient | $12,340.57 | 43 |
| PY2023 | Principal investigator | $3,058,770.58 | 554 |
| PY2022 | Recipient | $6,573.85 | 21 |
| PY2022 | Principal investigator | $3,959,470.39 | 564 |
| PY2021 | Recipient | $2,051.30 | 3 |
| PY2021 | Principal investigator | $3,633,687.21 | 452 |
| PY2020 | Recipient | $4,140.00 | 2 |
| PY2020 | Principal investigator | $3,869,603.69 | 702 |
| PY2019 | Recipient | $19,310.95 | 3 |
| PY2019 | Principal investigator | $5,330,060.34 | 887 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
363 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Ipsen Pharma SAS | $780.36 | 12/31/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303477 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,170.54 | 12/31/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303479 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,762.51 | 12/31/2025 | Non-covered Recipient Entity The Angeles Clinic and Research Institute | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma KEYMAKER-U02# Substudy 02D | No dispute reported | 06/30/2026 | 1232924598 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $17,426.75 | 12/31/2025 | Non-covered Recipient Entity The Angeles Clinic and Research Institute | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma KEYMAKER-U02# Substudy 02B | No dispute reported | 06/30/2026 | 1232924810 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,394.04 | 12/31/2025 | Non-covered Recipient Entity The Angeles Clinic and Research Institute | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma KEYMAKER-U02# Substudy 02A | No dispute reported | 06/30/2026 | 1232924854 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $6,285.48 | 12/31/2025 | Non-covered Recipient Entity The Angeles Clinic and Research Institute | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma KEYMAKER-U02# Substudy 02C | No dispute reported | 06/30/2026 | 1232925229 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $18,435.62 | 12/31/2025 | Non-covered Recipient Entity The Angeles Clinic and Research Institute | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | No dispute reported | 06/30/2026 | 1232926129 |
| Principal investigator 1 | PFIZER INC. | $12,183.06 | 12/31/2025 | Non-covered Recipient Entity CedarsSinai Medical Care Foundation | AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228816266 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $624.00 | 12/24/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252499213 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,057.18 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303865 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,361.68 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303867 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,082.18 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303869 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,057.18 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303871 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,792.57 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303873 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,890.78 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303875 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,890.78 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303877 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,082.18 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303879 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,887.18 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303881 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,057.18 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303883 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,361.68 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303885 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,792.57 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303887 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,767.28 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303889 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,890.78 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303891 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,890.78 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303893 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,792.57 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303895 |
| Principal investigator 1 | Ipsen Pharma SAS | $5,620.37 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303897 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,792.57 | 12/24/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303899 |
| Principal investigator 1 | Ipsen Pharma SAS | $724.00 | 12/23/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303471 |
| Principal investigator 1 | Ipsen Pharma SAS | $7,539.00 | 12/23/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303473 |
| Principal investigator 1 | Ipsen Pharma SAS | $195.09 | 12/19/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303467 |
| Principal investigator 1 | Ipsen Pharma SAS | $15,078.00 | 12/19/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303469 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $54.00 | 12/19/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244051667 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $14,116.71 | 12/19/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244051669 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $114.75 | 12/19/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244051671 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $472.50 | 12/19/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244051673 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,364.52 | 12/12/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303463 |
| Principal investigator 1 | Ipsen Pharma SAS | $6,226.15 | 12/12/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303465 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $6,250.00 | 12/11/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT02360579 | No dispute reported | 06/30/2026 | 1252498411 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $375.00 | 12/11/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT02360579 | No dispute reported | 06/30/2026 | 1252498413 |
| Principal investigator 1 | PFIZER INC. | $23,310.25 | 12/11/2025 | Non-covered Recipient Entity CedarsSinai Medical Care Foundation | AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228815412 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,641.06 | 12/11/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184274578 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,640.00 | 12/11/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184274580 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,500.00 | 12/11/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184274582 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $20,456.00 | 12/11/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184274584 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $37,821.00 | 12/11/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184274588 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,386.00 | 12/11/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184274590 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $13,300.82 | 12/11/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244051665 |
| Principal investigator 1 | Ipsen Pharma SAS | $68.00 | 12/08/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303475 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $146.25 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269757 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $594.18 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269759 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $146.07 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269761 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $292.05 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269763 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $146.25 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269765 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $409.32 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269767 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $146.25 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269769 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $238.23 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269771 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $409.68 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269773 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.52 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269775 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $146.07 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269777 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $145.98 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269779 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $146.25 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269781 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $72.54 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269783 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $78.57 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269785 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $78.57 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269787 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $78.57 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269789 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $146.25 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269791 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $146.25 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269793 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,814.67 | 12/08/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269795 |
| Principal investigator 1 | Ipsen Pharma SAS | $10,233.89 | 12/04/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303457 |
| Principal investigator 1 | Ipsen Pharma SAS | $6,234.41 | 12/04/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303459 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,170.54 | 12/04/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303461 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,967.00 | 12/02/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252499215 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $650.00 | 12/02/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252499217 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $63,513.05 | 12/01/2025 | Non-covered Recipient Entity The Angeles Clinic and Research Institute | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | No dispute reported | 06/30/2026 | 1232926127 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $35,130.00 | 11/26/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1236001645 |
| Principal investigator 1 | PFIZER INC. | $7,458.05 | 11/26/2025 | Non-covered Recipient Entity CedarsSinai Medical Care Foundation | AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228818432 |
| Principal investigator 1 | PFIZER INC. | $15,650.87 | 11/19/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228713674 |
| Principal investigator 1 | Ipsen Pharma SAS | $682.26 | 11/18/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303451 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,253.49 | 11/18/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303453 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,365.63 | 11/18/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303455 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,077.74 | 11/13/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT02360579 | No dispute reported | 06/30/2026 | 1252498409 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $521.10 | 11/07/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244051663 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,550.00 | 11/05/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184257451 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,092.00 | 11/05/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184257453 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.00 | 11/05/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184257455 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,950.00 | 11/05/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184257457 |
| Principal investigator 1 | PFIZER INC. | $20,108.25 | 11/04/2025 | Non-covered Recipient Entity CedarsSinai Medical Care Foundation | AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228818427 |
| Principal investigator 1 | Ipsen Pharma SAS | $147.00 | 10/31/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303449 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $585.00 | 10/29/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253939 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,304.88 | 10/09/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244051661 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $596.00 | 10/06/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252499211 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $58,662.92 | 10/06/2025 | Non-covered Recipient Entity The Angeles Clinic and Research Institute | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma KEYMAKER-U02# Substudy 02A | No dispute reported | 06/30/2026 | 1232924806 |
| Recipient | F. Hoffmann-La Roche AG | $1,271.58 | 09/26/2025 | Covered Recipient Physician | Morpheus Melanoma | No dispute reported | 06/30/2026 | 1211538094 |
| Principal investigator 1 | PFIZER INC. | $41,837.90 | 09/26/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 STUDY OF SEACD70 IN MYELOID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228824119 |
| Principal investigator 1 | PFIZER INC. | $25,516.40 | 09/26/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228824125 |
| Principal investigator 1 | PFIZER INC. | $11,313.60 | 09/26/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228824130 |
| Principal investigator 1 | Ipsen Pharma SAS | $8,412.10 | 09/25/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303857 |
| Principal investigator 1 | Ipsen Pharma SAS | $5,458.07 | 09/24/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303441 |
| Principal investigator 1 | Ipsen Pharma SAS | $25,069.83 | 09/24/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303443 |
| Principal investigator 1 | PFIZER INC. | $102,018.78 | 09/24/2025 | Non-covered Recipient Entity CedarsSinai Medical Care Foundation | AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228837528 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,341.08 | 09/19/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303447 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $430.30 | 09/19/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES | No dispute reported | 06/30/2026 | 1184241132 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $59,934.40 | 09/18/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | NCT02360579 | No dispute reported | 06/30/2026 | 1252498365 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,875.00 | 09/18/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | NCT02360579 | No dispute reported | 06/30/2026 | 1252498367 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $4,388.00 | 09/18/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | NCT02360579 | No dispute reported | 06/30/2026 | 1252498369 |
| Principal investigator 1 | Organon Llc | $1,800.25 | 09/18/2025 | Non-covered Recipient Entity Cedars Sinai Medical Care Foundation | 3475-587 | No dispute reported | 06/30/2026 | 1173042572 |
| Principal investigator 1 | Ipsen Pharma SAS | $357.50 | 09/17/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303847 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,600.00 | 09/17/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303849 |
| Principal investigator 1 | Ipsen Pharma SAS | $330.20 | 09/17/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303851 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,724.80 | 09/17/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303853 |
| Principal investigator 1 | Ipsen Pharma SAS | $288.60 | 09/17/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303855 |
| Principal investigator 1 | Ipsen Pharma SAS | $460.00 | 09/17/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303859 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,316.90 | 09/17/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303861 |
| Principal investigator 1 | Ipsen Pharma SAS | $928.20 | 09/17/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303863 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,814.67 | 09/17/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184239780 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,906.00 | 09/10/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497731 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $936.00 | 09/10/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497733 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,720.00 | 09/10/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497735 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,265.00 | 09/10/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497737 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $4,875.00 | 09/10/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497739 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,430.00 | 09/10/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497741 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $6,240.00 | 09/10/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497743 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $13,000.00 | 09/10/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497745 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,950.00 | 09/10/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497747 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $343.20 | 09/10/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497749 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $195.00 | 09/10/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497751 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $338.00 | 09/10/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497753 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $975.00 | 09/10/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497755 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,300.00 | 09/10/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497757 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $258.14 | 09/10/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184118179 |
| Principal investigator 1 | Incyte Corporation | $2,798.22 | 09/08/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601349 |
| Principal investigator 1 | Incyte Corporation | $79,636.51 | 09/08/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601352 |
| Principal investigator 1 | Incyte Corporation | $388.43 | 09/08/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601355 |
| Principal investigator 1 | Incyte Corporation | $388.43 | 09/08/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601358 |
| Principal investigator 1 | Incyte Corporation | $47.47 | 09/08/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601389 |
| Principal investigator 1 | Incyte Corporation | $4,388.79 | 09/08/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601395 |
| Principal investigator 1 | Incyte Corporation | $4,876.43 | 09/08/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601398 |
| Principal investigator 1 | Incyte Corporation | $4,876.43 | 09/08/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601402 |
| Principal investigator 1 | Incyte Corporation | $388.43 | 09/08/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601405 |
| Principal investigator 1 | Ipsen Pharma SAS | $195.09 | 09/05/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303445 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $15,752.12 | 09/04/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244051659 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $104.73 | 08/29/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184118177 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $14,116.71 | 08/21/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244051655 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $472.50 | 08/21/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244051657 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $17,772.06 | 08/07/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244051653 |
| Principal investigator 1 | Incyte Corporation | $650.00 | 08/06/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601378 |
| Principal investigator 1 | Incyte Corporation | $1,300.00 | 08/06/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601385 |
| Principal investigator 1 | Incyte Corporation | $1,755.00 | 08/06/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601392 |
| Principal investigator 1 | PFIZER INC. | $51,596.69 | 08/05/2025 | Non-covered Recipient Entity CedarsSinai Medical Care Foundation | AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228841301 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,370.00 | 07/31/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497955 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,371.00 | 07/31/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497957 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,872.00 | 07/31/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497959 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,790.43 | 07/31/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244051651 |
| Principal investigator 1 | Ipsen Pharma SAS | $68.00 | 07/30/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303431 |
| Principal investigator 1 | Ipsen Pharma SAS | $183.27 | 07/30/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303433 |
| Principal investigator 1 | Ipsen Pharma SAS | $147.00 | 07/30/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303435 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $596.00 | 07/25/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497729 |
| Principal investigator 1 | PFIZER INC. | $42,684.20 | 07/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228845758 |
| Principal investigator 1 | PFIZER INC. | $19,763.90 | 07/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228845829 |
| Principal investigator 1 | PFIZER INC. | $17,171.70 | 07/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228845838 |
| Principal investigator 1 | PFIZER INC. | $9,152.00 | 07/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228845846 |
| Principal investigator 1 | PFIZER INC. | $416.00 | 07/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228845854 |
| Principal investigator 1 | PFIZER INC. | $7,894.90 | 07/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228845902 |
| Principal investigator 1 | Incyte Corporation | $312.00 | 07/23/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601366 |
| Principal investigator 1 | Incyte Corporation | $624.00 | 07/23/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601381 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,724.80 | 07/23/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303821 |
| Principal investigator 1 | Ipsen Pharma SAS | $357.50 | 07/23/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303823 |
| Principal investigator 1 | Ipsen Pharma SAS | $598.00 | 07/23/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303825 |
| Principal investigator 1 | Ipsen Pharma SAS | $330.20 | 07/23/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303827 |
| Principal investigator 1 | Ipsen Pharma SAS | $330.20 | 07/23/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303829 |
| Principal investigator 1 | Ipsen Pharma SAS | $288.60 | 07/23/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303831 |
| Principal investigator 1 | Ipsen Pharma SAS | $288.60 | 07/23/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303833 |
| Principal investigator 1 | Ipsen Pharma SAS | $928.20 | 07/23/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303835 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,724.80 | 07/23/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303837 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,380.00 | 07/23/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303839 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,316.90 | 07/23/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303841 |
| Principal investigator 1 | Ipsen Pharma SAS | $180.70 | 07/23/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303843 |
| Principal investigator 1 | Ipsen Pharma SAS | $153.40 | 07/23/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303845 |
| Principal investigator 1 | PFIZER INC. | $34,725.00 | 07/22/2025 | Non-covered Recipient Entity CedarsSinai Medical Care Foundation | AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228847377 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,256.22 | 07/16/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES | No dispute reported | 06/30/2026 | 1184216958 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,943.60 | 07/11/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES | No dispute reported | 06/30/2026 | 1184214836 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,364.52 | 07/09/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303429 |
| Principal investigator 1 | Incyte Corporation | $2,600.00 | 07/02/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601362 |
| Principal investigator 1 | Incyte Corporation | $4,550.00 | 07/02/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601369 |
| Principal investigator 1 | Incyte Corporation | $1,092.00 | 07/02/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601373 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $130.00 | 07/01/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES | No dispute reported | 06/30/2026 | 1184212361 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 06/26/2025 | Non-covered Recipient Entity CedarsSinai Medical Care Foundation | AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228852365 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,839.60 | 06/25/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES | No dispute reported | 06/30/2026 | 1184210972 |
| Principal investigator 1 | Incyte Corporation | $14,251.00 | 06/23/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601197 |
| Principal investigator 1 | Incyte Corporation | $2,808.00 | 06/23/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601200 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $753.00 | 06/23/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184210254 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $66,240.00 | 06/20/2025 | Non-covered Recipient Entity Cedars Sinai Medical Care Foundation | A phase 1b,2, multicenter, open-label study of S-531011 as monotherapy and in combination with an immune checkpoint inhibitor in participants with locally advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1232935851 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,999.53 | 06/20/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184209882 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,093.55 | 06/19/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303427 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,375.00 | 06/19/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244051643 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,725.00 | 06/19/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244051645 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $13,500.00 | 06/19/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244051647 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $15,980.00 | 06/19/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244051649 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,887.18 | 06/18/2025 | Non-covered Recipient Entity Exceptional Care Medical Group | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184306833 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $331.50 | 06/16/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184206875 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $351.00 | 06/16/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184206877 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $403.00 | 06/16/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184207001 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $557.70 | 06/16/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184207119 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,392.00 | 06/16/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184207311 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,661.10 | 06/16/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184207333 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,542.50 | 06/16/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184207431 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $375.00 | 06/13/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | NCT02360579 | No dispute reported | 06/30/2026 | 1252497033 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $119.77 | 06/06/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184118175 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,077.74 | 06/05/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | NCT02360579 | No dispute reported | 06/30/2026 | 1252497027 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $421.00 | 06/02/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192166514 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,145.94 | 05/29/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184303425 |
| Principal investigator 1 | PFIZER INC. | $31,725.00 | 05/23/2025 | Non-covered Recipient Entity CedarsSinai Medical Care Foundation | AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228855642 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $6,250.00 | 05/22/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | NCT02360579 | No dispute reported | 06/30/2026 | 1252497029 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $375.00 | 05/22/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | NCT02360579 | No dispute reported | 06/30/2026 | 1252497031 |
| Principal investigator 1 | Incyte Corporation | $975.00 | 05/21/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601114 |
| Principal investigator 1 | Incyte Corporation | $2,090.00 | 05/21/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601204 |
| Principal investigator 1 | Ipsen Pharma SAS | $181.00 | 05/13/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184303423 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $23,039.50 | 05/08/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | NCT02360579 | No dispute reported | 06/30/2026 | 1252497035 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $3,461.00 | 05/07/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497409 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,080.00 | 05/07/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497411 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $3,461.00 | 05/07/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497413 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $489.00 | 05/07/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497471 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $4,550.00 | 05/07/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497475 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,950.00 | 05/07/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497477 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,092.00 | 05/07/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497479 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,361.68 | 05/05/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184303819 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $292.81 | 04/29/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184118173 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,950.00 | 04/28/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192166879 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $650.00 | 04/28/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192166887 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,500.00 | 04/28/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192170081 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $354.00 | 04/28/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192170090 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,057.18 | 04/25/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303813 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,792.57 | 04/25/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303815 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,890.78 | 04/25/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303817 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,500.00 | 04/23/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES | No dispute reported | 06/30/2026 | 1184189193 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,276.00 | 04/23/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES | No dispute reported | 06/30/2026 | 1184189195 |
| Principal investigator 1 | Immunocore Limited | $765.35 | 04/17/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma | No dispute reported | 06/30/2026 | 1212145703 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $275.64 | 04/11/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES | No dispute reported | 06/30/2026 | 1184183166 |
| Principal investigator 1 | Incyte Corporation | $405.55 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601118 |
| Principal investigator 1 | Incyte Corporation | $673.25 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601122 |
| Principal investigator 1 | Incyte Corporation | $673.25 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601125 |
| Principal investigator 1 | Incyte Corporation | $1,127.71 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601130 |
| Principal investigator 1 | Incyte Corporation | $97.35 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601133 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601137 |
| Principal investigator 1 | Incyte Corporation | $295.56 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601143 |
| Principal investigator 1 | Incyte Corporation | $607.56 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601147 |
| Principal investigator 1 | Incyte Corporation | $1,127.71 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601151 |
| Principal investigator 1 | Incyte Corporation | $427.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601155 |
| Principal investigator 1 | Incyte Corporation | $49.23 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601160 |
| Principal investigator 1 | Incyte Corporation | $2,168.34 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601164 |
| Principal investigator 1 | Incyte Corporation | $19.45 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601167 |
| Principal investigator 1 | Incyte Corporation | $815.71 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601172 |
| Principal investigator 1 | Incyte Corporation | $374.25 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601177 |
| Principal investigator 1 | Incyte Corporation | $1,127.71 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601181 |
| Principal investigator 1 | Incyte Corporation | $427.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601185 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601188 |
| Principal investigator 1 | Incyte Corporation | $1,127.71 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601192 |
| Principal investigator 1 | Incyte Corporation | $427.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601208 |
| Principal investigator 1 | Incyte Corporation | $2,533.43 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601211 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601215 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601219 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601223 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601228 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601232 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601236 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601238 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601242 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601246 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601249 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601254 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601258 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601261 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601264 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601267 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601272 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601276 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601282 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601286 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601290 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601294 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601298 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601301 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601305 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601308 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601312 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601316 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601320 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601324 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601328 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601331 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601337 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601341 |
| Principal investigator 1 | Incyte Corporation | $492.28 | 04/09/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601345 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $3,989.00 | 04/09/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497469 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $750.00 | 04/09/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497473 |
| Principal investigator 1 | PFIZER INC. | $32,050.54 | 04/07/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1228778871 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $396.99 | 04/05/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184118171 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $491.22 | 04/03/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184118169 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,895.60 | 04/02/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES | No dispute reported | 06/30/2026 | 1184181118 |
| Principal investigator 1 | Incyte Corporation | $18,713.10 | 03/28/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240601082 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,077.74 | 03/27/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | NCT02360579 | No dispute reported | 06/30/2026 | 1252497019 |
| Principal investigator 1 | Ipsen Pharma SAS | $124.44 | 03/27/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303413 |
| Principal investigator 1 | Ipsen Pharma SAS | $68.00 | 03/26/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303415 |
| Principal investigator 1 | Ipsen Pharma SAS | $147.00 | 03/26/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303417 |
| Principal investigator 1 | Ipsen Pharma SAS | $202.82 | 03/26/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303419 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,086.00 | 03/06/2025 | Non-covered Recipient Entity Cedars Sinai The Angeles Clinic And Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303421 |
| Principal investigator 1 | Incyte Corporation | $2,600.00 | 03/05/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601057 |
| Principal investigator 1 | Incyte Corporation | $357.14 | 03/05/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601078 |
| Principal investigator 1 | Incyte Corporation | $1,092.00 | 03/05/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601085 |
| Principal investigator 1 | Incyte Corporation | $975.00 | 03/05/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601092 |
| Principal investigator 1 | Incyte Corporation | $43,627.90 | 03/03/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601106 |
| Principal investigator 1 | Incyte Corporation | $1,300.00 | 03/03/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | No dispute reported | 06/30/2026 | 1240601109 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $12,000.00 | 02/27/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | NCT02360579 | No dispute reported | 06/30/2026 | 1252497025 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,736.10 | 02/27/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184155970 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $148.22 | 02/25/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184118167 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $366.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192166518 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,626.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192166523 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $345.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192166527 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $585.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192166530 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,603.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192166861 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,550.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192166865 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $95.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192166869 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,763.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192166874 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $585.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192166883 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $585.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192166891 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,040.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192170086 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $585.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192170095 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,950.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192170099 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,137.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192170103 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,955.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192170107 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $519.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192170111 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,038.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192170114 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,690.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192170484 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $90.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192170488 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,830.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192170492 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,550.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192170500 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $585.00 | 02/24/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE | A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST | No dispute reported | 06/30/2026 | 1192170504 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,527.00 | 02/21/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES | No dispute reported | 06/30/2026 | 1184155344 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $7,500.00 | 02/20/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | NCT02360579 | No dispute reported | 06/30/2026 | 1252497017 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $21,625.00 | 02/20/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | NCT02360579 | No dispute reported | 06/30/2026 | 1252497021 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $4,250.00 | 02/20/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | NCT02360579 | No dispute reported | 06/30/2026 | 1252497023 |
| Principal investigator 1 | Celgene Corporation | $15,866.00 | 02/14/2025 | Non-covered Recipient Entity Cedars Sinai Medical Care Foundation Pharmacy | A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222305722 |
| Principal investigator 1 | Celgene Corporation | $15,184.00 | 02/14/2025 | Non-covered Recipient Entity Cedars Sinai Medical Care Foundation Pharmacy | A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222305784 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $238.92 | 02/14/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184118163 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $230.40 | 02/14/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184118165 |
| Principal investigator 1 | Incyte Corporation | $1,092.00 | 02/05/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240601062 |
| Principal investigator 1 | Incyte Corporation | $650.00 | 02/05/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240601066 |
| Principal investigator 1 | Incyte Corporation | $4,550.00 | 02/05/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240601070 |
| Principal investigator 1 | Incyte Corporation | $1,755.00 | 02/05/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240601074 |
| Principal investigator 1 | Incyte Corporation | $750.00 | 02/05/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240601095 |
| Principal investigator 1 | Incyte Corporation | $2,600.00 | 02/05/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240601099 |
| Principal investigator 1 | Incyte Corporation | $1,300.00 | 02/05/2025 | Non-covered Recipient Entity THE ANGELES CLINIC AND RESEARCH INSTITUTE | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240601102 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $588.00 | 01/27/2025 | Non-covered Recipient Entity Cedars-Sinai Medical Center | NCT05361174 | No dispute reported | 06/30/2026 | 1252497349 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $30,491.00 | 01/17/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab andNivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma [RELAtivity-098] | No dispute reported | 06/30/2026 | 1236001643 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $47,600.77 | 01/14/2025 | Non-covered Recipient Entity CEDARSSINAI MEDICAL CARE FOUNDATION | A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma | No dispute reported | 06/30/2026 | 1190309166 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,250.00 | 01/10/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303801 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,300.00 | 01/10/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303803 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,640.00 | 01/10/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303805 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,000.00 | 01/10/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303807 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,550.00 | 01/10/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303809 |
| Principal investigator 1 | Ipsen Pharma SAS | $13,000.00 | 01/10/2025 | Non-covered Recipient Entity Cedars Sinai Internal Medicine Encino | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184303811 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $103,786.28 | 01/09/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1184147331 |
| Principal investigator 1 | Eli Lilly and Company | $4,554.00 | 01/03/2025 | Non-covered Recipient Entity CEDARS SINAI MEDICAL CARE FOUNDATION | Not supplied | No dispute reported | 06/30/2026 | 1187883368 |